gM/gN (gcII Complex) |
Major glycoprotein constituent of virion
Majority of human sera contain anti-gcII antibodies
gM/gN DNA vaccine immunogenic in mice
|
gH/gL/gO (gcIII Complex) |
|
Essential/Nonstructural Gene Products as Novel CTL Targets |
|
Prime/Boost Strategy |
Prime with cocktail of plasmid DNA vaccines
Boost with formalin-inactivated viral particles
Induces “sterilizing immunity” in MCMV model
|
Bacterial Artificial Chromosome (BAC) Vaccines |
Protective in MCMV model following delivery in bacteria with reconstitution of virus in vivo
Protective in GPCMV model when administered as replication-disabled DNA vaccine
Offers potential for specifically engineered vaccines
|
Peptide Vaccines |
Effective in MCMV model following mucosal immunization with cholera toxin
Allows simultaneous immunization against broad range of CTL epitopes: “polyepitope” vaccine
Requires knowledge of HLA status; best suited to HCMV vaccination in transplantation setting?
|
“Dense Body” Vaccines
|
Noninfectious particles enriched for envelope glycoproteins and pp65, major subunit vaccine candidates
Highly immunogenic in animal models
Humoral and cell-mediated immune responses
Can be engineered to express heterologous genes
|